Anacor Pharmaceuticals today announced the appointment of Geoffrey M. Parker as Senior Vice President and Chief Financial Officer. Mr. Parker will be responsible for managing the company’s finance operations as well as its business development and investor relations functions.
“As Anacor continues to explore the therapeutic and commercial potential of our boron-based chemistry platform, Geoff’s deep knowledge of the biotechnology and pharmaceutical industry and experience in corporate finance, structuring and valuing transactions, strategic planning and executive management, make him an invaluable asset to our company,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “The Board of Directors joins me in welcoming Geoff to his new position and looks forward to leveraging his many talents to support Anacor’s growth and maturation.”
Mr. Parker served as a consultant to Anacor from December 2009 to his current appointment as Chief Financial Officer. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of Genoptix, Inc., a specialized laboratory service provider and ChemoCentryx, Inc., a clinical-stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford University.
No comments:
Post a Comment